Dr Gautham Shenoy G
Professor
Date of Joining: 14.08.1991
Department of Pharmaceutical Chemistry
CURRENT ACADEMIC ROLE & RESPONSIBILITIES
- He Is an approved guide for PG and PhD students.
- He Involves in administrative responsibilities
Dr. G Gautham Shenoy
SUBJECTS CURRENTLY TEACHING
Subject | Semester / Year |
---|---|
Advanced Medicinal Chemistry | First Semester MPharm |
Pharmaceutical Chemistry Practical-I | First Semester MPharm |
Pharmaceutical Validation | First Semester MPharm |
ACADEMIC QUALIFICATIONS
Degree | Specialisation | Institute | Year of passing |
---|---|---|---|
PhD | Mangalore University | 1999 | |
MPharm | Pharmaceutical Chemistry | Manipal College of Pharmaceutical Sciences, Manipal | 1991 |
Experience
Institution / Organisation | Designation | Role | Tenure |
---|---|---|---|
Department of Pharmaceutics, MCOPS, Manipal Academy of Higher Education | Professor | 2009 | |
Department of Pharmaceutics, MCOPS, Manipal Academy of Higher Education | Associate Professor | 2004 | |
Department of Pharmaceutics, MCOPS, Manipal Academy of Higher Education | Associate Professor | 1993 | |
Department of Pharmaceutics, MCOPS, Manipal Academy of Higher Education | Lecturer | 1991 |
Anti-tubercular activity
Received grants from the following funding agencies: DST, New Delhi (Co-Principal Investigator) ICMR, New Delhi (Principal Investigator) AICTE, New Delhi (Principal Investigator) DBT, New Delhi (Co- Investigator)
AREAS OF INTEREST, EXPERTISE AND RESEARCH
Area of Interest
Drug Design, Preclinical Studies
Area of Expertise
Organic Synthesis, Chromatography, In-vitro Screening Techniques for Antitubercular Activity, Physicochemical Properties.
Area of Research
Antitubercular Drug Discovery
Professional Affiliations & Contributions
- Life Member of APTI, India, 2010.
- Life Member of NMRS, India, 2008.
Fabrication, solid state characterization and bioavailability assessment of stable binary amorphous phases of Ritonavir with Quercetin
SJ Dengale SS Hussen BSM Krishna PB Musmade GG Shenoy KM Bhat
European Journal of Pharmaceutics and Biopharmaceutics., 2015 89, 329-338
Synthesis and Evaluation of Antitubercular Activity of Novel Diphenyl Ether Derivatives
CA Thomas SS Kar I Bairy VG Bhat VP Shenoy GG Shenoy
Indo Global Journal of Pharmaceutical Sciences. 2015, 5 (1), 19-25
Production of β-cyclodextrin from pH and thermo stable cyclodextrin glycosyl transferase, obtained from arthrobacter mysorens and its evaluation as a drug carrier for Irbesartan
Rajesh, Y Narayanan, K Srinivas Reddy M Vijaya bhaskar K Gautham G Shenoy Subramanyam VM Venkata Rao J
Current Drug Delivery, 2015, 12. pp. 1-10
In-vitro bactericidal activity of recombinant lysostaphin on biofilm producing methicillin resistant Staphylococcus aureus.
N Narasimhaswamy I Bairy A Manuel J Mathew G Shenoy L Bairy
Int. J. Curr. Microbiol. App. Sciences, 2015, 4 (1), 822-830
Preparation and characterization of co-amorphous Ritonavir–Indomethacin systems by solvent evaporation technique: Improved dissolution behavior and physical stability without evidence of intermolecular interactions.
SJ Dengale OP Ranjan SS Hussen BSM Krishna PB Musmade GG Shenoy KM Bhat
European Journal of Pharmaceutical Sciences, 2014, 62, 57-64
5-[(substituted -phenylamino)-methyl]-2-phenoxy-phenols and synthesis thereof. Indian Patent application number: 321/CHE/2015
ICMR funded project
Dr Sidharth SankarKar
Enoyl Acyl Carrier protein reeducates enzyme of Mycobacterium tuberculosis is part of type II Fatty acid synthase and is involved in the biosynthesis of mycolic acid. It is considered to be one of the ideal targets for drug discovery. Triclosan, a dipehyl ether derivative has moderate antitubercular activity. Encouraged by the outcome of the earlier work carried out in our laboratory, it was decided to explore diphenyl ethers further for antitubercular activity. In the present study, diphenyl ether derivatives have been designed with the help of docking studies and evaluated for antitubercular activity. 18 compounds had MIC ≤ 12.5 µg/mL. Few compounds possessed promising activity against Isoniazid resistant and MDR strains of Mycobacterium tuberculosis.